

Literatur für onkologie heute 8/2020

SCHWERPUNKT: UROLOGISCHE TUMOREN

Lokale radioonkologische Therapie bei oligometastasierten urologischen Tumoren (S. 31–36)

T. Sprave, C. Zamboglou, R. Wiehle, A.-L. Grosu und T. Wiegel

1. Hellman S, Weichselbaum RR. Oligometastases. *J Clin Oncol* 1995; 13(1): 8–10
2. Gudem G et al. The evolutionary history of lethal metastatic prostate cancer. *Nature* 2015; 520(7547): 353–7
3. Parker CC et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. *Lancet* 2018; 392(10162): 2353–66
4. Weichselbaum RR, Hellman S. Oligometastases revisited. *Nat Rev Clin Oncol* 2011; 8(6): 378–82
5. Kneebone A et al. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. *Eur Urol Oncol* 2018; 1(6): 531–7
6. Liu W et al. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. *Int J Radiat Oncol Biol Phys* 2020; 106(3): 546–55
7. Ong WL et al. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature. *BJU Int* 2019; 124 Suppl 1: 19–30
8. Battaglia A et al. Metastasectomy for visceral and skeletal oligorecurrent prostate cancer. *World J Urol* 2019; 37(8): 1543–9
9. Naito S et al. Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. *Urology* 2013; 82(4): 846–51
10. Svedman C et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. *Acta Oncologica (Stockholm, Sweden)* 2006; 45(7): 870–5
11. De Bruycker A et al. Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. *BJU Int* 2017; 120(6): 815–21
12. Singh D et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? *Int J Radiat Oncol Biol Phys* 2004; 58(1): 3–10
13. Motzer RJ et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. *J Clin Oncol* 1999; 17(8): 2530–40
14. De Bruycker A et al. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. *Eur Urol* 2019; 75(5): 826–33
15. Hoerner-Rieber J et al. Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma—a multicenter analysis of the German working group "Stereotactic Radiotherapy". *J Thorac Dis* 2017; 9(11): 4512–22
16. Rieber J et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases—A pooled analysis of the German working group "stereotactic radiotherapy". *Lung Cancer* 2016; 97: 51–8
17. Adebahr S et al. Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life: Benefit for Patients With Low Initial Scores (STRIPE Trial). *J Thorac Oncol* 2019; 14(3): 408–19
18. Sprave T et al. Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. *Radiother Oncol* 2018; 128(2): 274–82

19. Sprave T et al. Quality of Life Following Stereotactic Body Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: Secondary Analysis of an Exploratory Phase II Randomized Trial. *Anticancer Research* 2018; 38(8): 4961–8
20. Widder J et al. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy? *Radiother Oncol* 2013; 107(3): 409–13
21. Ost P et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. *J Clin Oncol* 2018; 36(5): 446–53
22. Klement RJ et al. Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. *Radiother Oncol* 2018; 127(2): 246–52
23. Jilg CA et al. Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)F/(11)C-choline positron emission tomography/computerized tomography. *JUrol* 2014; 192(1): 103–10
24. Rischke HC et al. PET/CT and MRI directed extended salvage radiotherapy in recurrent prostate cancer with lymph node metastases. *Adv Med Sci* 2016; 61(2): 212–8
25. De Bleser E et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. *Eur Urol* 2019; 76(6): 732–9
26. Siva S et al. Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. *Eur Urol* 2018; 74(4): 455–62
27. Phillips Ret al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. *JAMA Oncol* 2020 Mar 26; 6(5): 650–659
28. Bowden P et al. Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. *Int J Cancer* 2020; 146(1): 161–8
29. Steuber T et al. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study. *Eur Urol Focus* 2019; 5(6): 1007–13
30. Fanetti G et al. Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases. *Med Oncol* 2018; 35(5): 75
31. Triggiani L et al. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. *World J Urol* 2019; 37(12): 2631–7
32. Zaorsky NG et al. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. *Eur Urol Oncol* 2019; 2(5): 515–23
33. Ranck MC et al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. *Am J Clin Oncol* 2013; 36(6): 589–95
34. Franzese C et al. Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. *J Urol* 2019; 201(1): 70–6
35. Wersall PJ et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. *Radiother Oncol* 2005; 77(1): 88–95
36. Zelefsky MJ et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. *Int J Radiat Oncol Biol Phys* 2012; 82(5): 1744–8
37. Nguyen QN, et al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. *Int J Radiat Oncol Biol Phys* 2010; 76(4): 1185–92
38. Meyer E et al. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group. *Eur J Cancer* 2018; 98: 38–47
39. von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *J Clin Oncol* 2000; 18(17): 3068–77

40. Galsky MD et al. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. *J Clin Oncol* 2020; 38(16): 1797–806
41. Iwamoto H et al. Metastasectomy Improves Survival in Patients with Metastatic Urothelial Carcinoma. *Anticancer Res* 2016; 36(10): 5557–61
42. Franzese Cet al. Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies. *Clin Oncol (R Coll Radiol)* 2020 Jul 25; S0936-6555(20)30290-9
43. Francolini G et al. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience. *Cancer Treat Res Commun* 2019; 19: 100124
44. Sundahl N et al. Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. *Eur Urol* 2019; 75(5): 707–11
45. Chiang A et al. Pain flare is a common adverse event in steroid-naive patients after spine stereotactic body radiation therapy: a prospective clinical trial. *Int J Radiat Oncol Biol Phys* 2013; 86(4): 638–42
46. Cunha MV et al. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors. *Int J Radiat Oncol Biol Phys* 2012; 84(3): e343–9
47. Thibault I et al. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture. *J Neurosurg Spine* 2014; 21(5): 711–8
48. Sahgal A et al. Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. *Lancet Oncol* 2013; 14(8): e310–20
49. Bijl HP et al. Dose-volume effects in the rat cervical spinal cord after proton irradiation. *Int J Radiat Oncol Biol Phys* 2002; 52(1): 205–11
50. Hopewell JW, Morris AD, Dixon-Brown A. The influence of field size on the late tolerance of the rat spinal cord to single doses of X rays. *Br J Radiol* 1987; 60(719): 1099–108
51. Sahgal A et al. Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy. *Int J Radiat Oncol Biol Phys* 2019 Oct 10; S0360-3016(19)33862-3
52. Ryu S et al. RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: phase 2 results. *Pract Radiat Oncol* 2014; 4(2): 76–81
53. Guckenberger M et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. *Lancet Oncol* 2020; 21(1): e18–e28